Vanguard Global Advisers
ABEO icon

Vanguard Global Advisers’s Abeona Therapeutics ABEO Stock Holding History

Vanguard Global Advisers’s Portfolio ABEO Stock Details ABEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$115K Hold
18,608
– – ﹤0.01% 2721
2026
Q1 		$83.4K Buy
+18,608
New +$93K ﹤0.01% 2802

Other funds holding ABEO

NCM
Nantahala Capital Management New Canaan, Connecticut $3B AUM 119.43% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CCC
Cable Car Capital San Francisco, California $4.66B AUM 77.16% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
OIA
OneDigital Investment Advisors Overland Park, Kansas $11.8B AUM 21.23% 1-Year Est. Return
AIC
AWM Investment Company New York $1.15B AUM 201.65% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $5.65B AUM 61.31% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Vanguard Global Advisers's ABEO Position: Q2 2026 in Review

Vanguard Global Advisers held its Abeona Therapeutics (ABEO) position steady in Q2 2026 at 18,608 shares worth $115K. The position accounts for ﹤0.01% of the portfolio, ranked #2721.

Vanguard Global Advisers first reported a position in ABEO in Q1 2026 and has held it in 2 quarters since. 126 funds tracked by Wall St. Rank hold ABEO as of Q2 2026.

  • Vanguard Global Advisers held 18,608 shares of Abeona Therapeutics worth $115K as of Q2 2026.
  • Vanguard Global Advisers left its Abeona Therapeutics share count unchanged in Q2 2026.
  • Abeona Therapeutics made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q2 2026, its #2721 holding.
  • Vanguard Global Advisers first reported a position in Abeona Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 126 funds tracked by Wall St. Rank held Abeona Therapeutics as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.